<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04247490</url>
  </required_header>
  <id_info>
    <org_study_id>637/2019/Oss/AOUFe</org_study_id>
    <nct_id>NCT04247490</nct_id>
  </id_info>
  <brief_title>Autoimmune Hepatitis in Pediatric Patients</brief_title>
  <official_title>Multicentric Study on the Long-term Follow-up of Autoimmune Hepatitis in the Pediatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of Ferrara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital of Ferrara</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autoimmune hepatitis (AIH) is an immune-mediated and inflammatory liver disorder. It is
      currently divided into types 1 and 2, differentiated and defined by the presence of specific
      autoantibodies. The objectives are to describe the prevalence and incidence of type 1 and 2
      autoimmune hepatitis and to analyze the clinics, biochemical and histopathological profiles
      at diagnosis and follow-up, initial therapy, response to therapy and long-term follow-up in
      three Italian centers of patients with type 1 and type 2 AIH.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Autoimmune hepatitis (AIH) is an immune-mediated and inflammatory liver disorder
      with typical onset in pediatric age. It is currently divided into types 1 and 2,
      differentiated and defined by the presence of specific autoantibodies. AIH type 1 (AIH-1) is
      characterised by smooth muscle and/or antinuclear autoantibodies (SMA/ANA) while anti-liver
      kidney microsomal (anti-LKM) or liver cytosol type 1 (anti-LC1) identified AIH type 2
      (AIH-2). The conventional treatment is based on corticosteroids and azathioprine as first
      line therapy. The optimal duration is not clear definied, however it should be extended for
      at least five years due to the frequent relapses.

      Aims of the study: The primary objective is to describe the prevalence and incidence of type
      1 and 2 autoimmune hepatitis on a selected italian pediatric population. Secondary objectives
      are to analyze the clinical, biochemical and histopathological profiles at diagnosis and
      follow-up, type of treatment received, response to therapy and long-term follow-up.

      Methods: The investigators conducted a retrospective and prospective cohort study on patients
      aged ≤ 18 years who the diagnosis of AIH 1 and 2 between 01/01/1989 and 31/12/2019 and were
      followed in three Italian pediatric centers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 17, 2019</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence and incidence</measure>
    <time_frame>from 01/01/1989 to 31/12/2019</time_frame>
    <description>The primary objective was to calculate the proportion of AIH type 1 and 2 patients present in the Italian pediatric population at a given time (prevalence) and the proportion of new AIH type 1 and 2 patients in the Italian pediatric population (0-18 years) in a given period of time (incidence).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characteristics of AIH in pediatric patients</measure>
    <time_frame>from 01/01/1989 to 31/12/2019</time_frame>
    <description>Describe the baseline characteristics (age of onset, clinical-laboratory, radiological and histological characteristics), the response to therapy (medical and / or the possible use of liver transplantation) and the follow-up of patients with autoimmune hepatitis type 1 and 2.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">109</enrollment>
  <condition>Autoimmune Hepatitis</condition>
  <arm_group>
    <arm_group_label>Pediatric AIH</arm_group_label>
    <description>Patients diagnosed with hepatitis type 1 and type 2 formulated between the ages of 0 and 18.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>pediatric AIH</intervention_name>
    <description>pediatric patients with clinical, laboratory (transaminase and IgG increase), instrumental (ultrasound, liver biopsy) characteristics</description>
    <arm_group_label>Pediatric AIH</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population is represented by all the patients who presented the onset of
        Autoimmune hepatitis type 1 and type 2 from 01/01/1989 to 31/12/2019 and were followed at
        the Pediatric Hepatology Centers of Ferrara (Hospital Saint Anna of Cona), Naples (Federico
        II University Hospital) and Palermo (Mediterranean Institute for Transplants and Highly
        Specialized Therapies).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≤ 18 years at the time of diagnosis

          -  Diagnosis of autoimmune hepatitis type 1 or 2 according to the Mieli-Vergani score: a
             pre-treatment score&gt; 15 or post-treatment&gt; 17 indicates a definite diagnosis of
             Autoimmune Hepatitis; a pre-treatment score between 10 and 15 or post-treatment
             between 12 and 17 indicates a probable diagnosis.

        Exclusion Criteria:

          -  Age&gt; 18 years at the time of diagnosis

          -  Presence of other causes of liver disease

          -  Presence of overlap syndrome (hepatito-cholangitis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital of Ferrara</name>
      <address>
        <city>Cona</city>
        <state>Ferrara</state>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Jiménez-Rivera C, Ling SC, Ahmed N, Yap J, Aglipay M, Barrowman N, Graitson S, Critch J, Rashid M, Ng VL, Roberts EA, Brill H, Dowhaniuk JK, Bruce G, Bax K, Deneau M, Guttman OR, Schreiber RA, Martin S, Alvarez F. Incidence and Characteristics of Autoimmune Hepatitis. Pediatrics. 2015 Nov;136(5):e1237-48. doi: 10.1542/peds.2015-0578. Epub 2015 Oct 19.</citation>
    <PMID>26482664</PMID>
  </reference>
  <results_reference>
    <citation>Verma S, Torbenson M, Thuluvath PJ. The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology. 2007 Dec;46(6):1828-35.</citation>
    <PMID>17705297</PMID>
  </results_reference>
  <results_reference>
    <citation>Nastasio S, Sciveres M, Matarazzo L, Maggiore G. Old and New Treatments for Pediatric Autoimmune Hepatitis. Curr Pediatr Rev. 2018;14(3):187-195. doi: 10.2174/1573396314666180516130314. Review.</citation>
    <PMID>29766815</PMID>
  </results_reference>
  <results_reference>
    <citation>Maggiore G, Porta G, Bernard O, Hadchouel M, Alvarez F, Homberg JC, Alagille D. Autoimmune hepatitis with initial presentation as acute hepatic failure in young children. J Pediatr. 1990 Feb;116(2):280-2.</citation>
    <PMID>2299503</PMID>
  </results_reference>
  <results_reference>
    <citation>Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WG, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston AL, Fainboim L, Heathcote J, Homberg JC, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RN, Maddrey WC, Manns MP, McFarlane IG, Meyer zum Büschenfelde KH, Zeniya M, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999 Nov;31(5):929-38.</citation>
    <PMID>10580593</PMID>
  </results_reference>
  <results_reference>
    <citation>Mieli-Vergani G, Vergani D, Baumann U, Czubkowski P, Debray D, Dezsofi A, Fischler B, Gupte G, Hierro L, Indolfi G, Jahnel J, Smets F, Verkade HJ, Hadžić N. Diagnosis and Management of Pediatric Autoimmune Liver Disease: ESPGHAN Hepatology Committee Position Statement. J Pediatr Gastroenterol Nutr. 2018 Feb;66(2):345-360. doi: 10.1097/MPG.0000000000001801.</citation>
    <PMID>29356770</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 20, 2020</study_first_submitted>
  <study_first_submitted_qc>January 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2020</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital of Ferrara</investigator_affiliation>
    <investigator_full_name>Giuseppe Maggiore</investigator_full_name>
    <investigator_title>Full Professor</investigator_title>
  </responsible_party>
  <keyword>Autoimmune hepatitis</keyword>
  <keyword>incidence</keyword>
  <keyword>prevalence</keyword>
  <keyword>immunosuppressive treatmen</keyword>
  <keyword>liver transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Autoimmune</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

